CORE--CLINICAL AND RESEARCH

阿尔茨海默病（AD）的持续科学进展依赖于仔细评估的患者和对照研究的可用性。临床研究开发核心的主要目标是通过提供记忆投诉患者的基本诊断评估，促进遗传家族研究和Bryan ADRC的其他多学科工作。自1990年以来，我们已经评估了Bryan ADRC神经疾病诊所（NDC）的5000多名新患者。我们计划专注于AD和其他相关痴呆患者的持续高质量评估和治疗。我们还提出了一些方法，以继续发展我们的多元文化临床服务，以老年非裔美国人和社区中的其他有色人种。确定AD和其他迟发性痴呆的遗传研究的家庭。有超过75个家庭在该中心登记，其中有多个产生的证据与尸检确认的AD。我们计划继续开发和评估更多的信息家庭。与杜克人类遗传学中心（DCHG）合作，我们还打算使用同胞对分析的新遗传学方法来研究AD患者的未受影响的同胞，以确定其他易感基因。继续在Bryan ADRC尸检项目中积极招募选定的患者和正常对照。目前，我们每年至少进行70次尸检，并随访100多名AD患者和约200名非痴呆对照。在补助金期间，我们将继续我们目前的招生和临床评估的做法，但我们也将作出强有力的重点努力，增加少数民族招生在正常控制和痴呆协议的尸检计划。促进阿尔茨海默病的临床研究。临床核心将继续成为Bryan ADRC研究的资源，外部研究将继续通过对AD风险增加的认知正常受试者进行系统性纵向研究来确定AD的最早临床表型。

The continuing scientific progress in Alzheimer's disease (AD) relies on the availability of carefully evaluated patients and controls for study. The main goal of the Clinical Research Development Core is to facilitate genetic family studies and other multi-disciplinary efforts of the Bryan ADRC by providing the basic diagnostic assessment of patients with memory complaints. We have evaluated over 5000 new patients in the Neurological Disorders Clinic (NDC) of the Bryan ADRC since 1990. We plan to focus on continued high-quality evaluation and treatment of patients with AD and other related dementias. We also propose methods to continue to develop our multi-cultural clinical services to elderly African American and other people of color in the community. Identify families for genetic studies of AD and other late onset dementias. There are over 75 families enrolled in the Center in which there is multi- generated evidence of AD with autopsy confirmation. We plan to continue to develop and evaluate additional informative families. In conjunction with the Duke Center for Human Genetics (DCHG), we also intend to study unaffected siblings of AD patients using new genetic methods of sib-pair analysis, in an effort to identify other susceptibility genes. Continue the active enrollment of selected patients and normal controls in the Bryan ADRC autopsy program. Currently, we conduct at least 70 autopsies per year and follow over 100 patients with AD and approximately 200 non-demented controls. During the grant period we will continue our current enrollment and clinical evaluation practices but we will also make a strong focused effort on increasing minority enrollment in both the normal control and dementia protocols of the autopsy program. Facilitate clinical research studies of Alzheimer's disease. The Clinical Core will continue to be a resource to the research studies of the Bryan ADRC, and to external studies continues to be to define the earliest clinical phenotype of AD through systematic longitudinal study of cognitively normal subjects at enhanced risk of AD.